Three Poster Presentations for XL184 in a Phase 2 Glioblastoma Trial

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 21, 2009-- Exelixis, Inc. (Nasdaq:EXEL) announced today that data from clinical trials of the company's investigational compounds XL184, XL147, XL765, XL228, and XL281 will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009 in Orlando, Florida. Interim data from an ongoing phase 2 clinical trial of XL184 in patients with progressive glioblastoma multiforme in first or second relapse will be described in three poster presentations. Interim data from ongoing phase 1 clinical trials of XL147, XL765, and XL281 in patients with advanced solid tumors, and XL228 in patients with advanced solid tumors or hematologic malignancies will be described in four separate oral presentations. Exelixis is co-developing XL184 with Bristol-Myers Squibb Company and has out-licensed XL281 to Bristol-Myers Squibb Company for further development, but continues to conduct the ongoing phase 1 trials.

XL184 Poster Presentations

• “A Phase 2 study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse” will be presented on Sunday, May 31, 2009, during the 8 a.m.-noon session (Abstract #2047)
• “Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: results from a Phase 2 study” will be presented on Sunday, May 31, 2009, during the 8 a.m.-noon session (Abstract #2048)
• “Correlative tumor molecular profiling and plasma biomarker analysis in a Phase 2 study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM)” will be presented on Sunday, May 31, 2009, during the 8 a.m.-noon session (Abstract #2049)

Oral Presentations

• “A Phase 1 study of XL228, a potent IGF1R / AURORA / SRC inhibitor, in patients with solid tumors or hematologic malignancies” will be presented on Saturday, May 30, 2009, starting at 4:15 p.m. local time (Abstract #3512)
• “A Phase 1 study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors” will be presented on Saturday, May 30, 2009, starting at 4:30 p.m. local time (Abstract #3513)
• “Phase 1 dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors” will be presented on Monday, June 1, 2009, starting at 1:30 p.m. local time (Abstract #3500)
• “A Phase 1 dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors” will be presented on Monday, June 1, 2009 starting at 2:00 p.m. local time (Abstract #3502)

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company’s web site at www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.

Source: Exelixis, Inc.

Exelixis, Inc.
Investor Contact:
Charles Butler, 650-837-7277
Executive Director, Corporate Communications
cbutler@exelixis.com
or
Media Contact:
Soleil Maxwell Harrison, 650-837-7012
Senior Manager, Corporate Communications
sharrison@exelixis.com